Business
Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
- IMM20059, Immunome’s epsin 1 (EPN1)-specific antibody, binds to the surface of multiple tumor cell lines, including lung, breast and prostate cancers in
About this update from Immunome, Inc.
[{"type":"text","content":"\n- IMM20059, Immunome’s epsin 1 (EPN1)-specific antibody, binds to the surface of multiple tumor cell lines, including lung, breast and prostate cancers in preclinical testing -\n\n- EPN1 appears to play an important role in cancer formation and progression, and IMM20059 may have the ability to improve response to immunotherapy -\n\n- Combinatorial effect (> 50% reduction in tumor volume) was demonstrated with IMM20059 and anti-PD-L1 treatment atezolizumab -\n\n EXTON, Pa.--(BUSINESS WIRE)--\nImmunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that it is presenting a poster at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting in Boston, Massachusetts highlighting the Company’s preclinical data of IMM20059, a novel anti-epsin 1(EPN1) antibody.\n\n“We continue to be pleased with the robust capabilities of our Discovery Engine to identify novel anti-tumor targets, including those that are abnormally (ectopically) expressed on tumor cells which have the potential to fundamentally shift treatment paradigms,” commented Purnanand Sarma, PhD, President and CEO of Immunome. “While further preclinical work will be required, we are quite encouraged by the results presented at SITC today. Treatment with the IMM20059 + atezolizumab combination resulted in over a 50% reduction in tumor volume (p","length":1949,"tagName":"div"}]